The essential components of this model—required training before being permitted to prescribe; a federal–medical society collaboration to develop curriculum; and a federal–medical society collaboration to provide training and support systems—are useful but would need substantial additional legislative and fiscal support to meet the goals of the FDA vis-à-vis REMS. Shortcomings of DATA 2000 are also instructive: Training and support services have not resulted in uniform exemplary practices, perhaps due to the absence of competency-based prescribing. Congress should provide federal agencies with the funding and authority to orchestrate a robust prescriber training and ongoing support system created and administered through a government–academia–medical society partnership similar to the one created in the wake of DATA 2000. This would be no small task: There were just over 1 million physicians registered with the DEA in 2009. Thus, training would need to be implemented in a gradual, rolling fashion, perhaps tied to renewal, so that access to needed medications would not be significantly compromised. Training should be of adequate content and scope—at least 8 hours of skills-based, interactive training—with recurring competency-based assessment (15). In addition to the worthwhile content outlined in the Blueprint, the scope should be expanded to include other controlled substances (e.g., short-acting opioids, benzodiazepines, and stimulants) that are often co-prescribed and have contributed to prescription drugs being more commonly abused than all illicit substances except marijuana. This would be entirely in keeping with the FDA's authority to “require a manufacturer to develop a REMS when the FDA finds a REMS is necessary to ensure that the benefits of a drug outweigh its risks” (4).